iMDx to Release First Quarter 2026 Results on May 13, 2026
Insight Molecular Diagnostics (Nasdaq: IMDX) will release its first quarter 2026 financial results after market close on May 13, 2026.
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) will release its first quarter 2026 financial results after market close on May 13, 2026. A live Zoom webinar to discuss results and host Q&A is scheduled for 2:00 pm PT / 5:00 pm ET that day, with registration required. An archived replay will be posted in the Investors/Events & Presentations section of iMDX’s website after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IMDX
In the May 7 session, IMDX declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings report date
- May 13, 2026
- Q1 2026 results to be reported after market close
- Webinar time PT
- 2:00 pm PT
- Live Zoom webinar to discuss Q1 2026 results
- Webinar time ET
- 5:00 pm ET
- Same-day Q1 2026 results discussion with Q&A
Previous Earnings date Reports
-
Set Q4 2025 earnings date and investor webinar with conference participation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX’s website within the Investors/Events & Presentations section here.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com


FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.